Tevogen Bio, a Warren-based clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, on Wednesday announced its Artificial Intelligence effort, Tevogen AI, has joined Microsoft for Startups. This partnership marks a significant milestone for Tevogen, providing unparalleled access to Microsoft’s extensive ecosystem.
The partnership is set to accelerate and streamline the development of Tevogen’s proprietary algorithms, significantly advancing its mission to lower the total cost of drug development, expedite drug discovery, and deliver life-changing therapies to large patient populations.
Mittul Mehta, CIO and head of Tevogen AI commented “The leadership at Tevogen Bio is extremely optimistic about the future for Tevogen as a partner with Microsoft. Joining Microsoft for Startups underscores Microsoft’s conviction in Tevogen’s ability to not only innovate, but also deliver.” The partnership with Microsoft, the leading innovator in the AI space, is a substantial investment in Tevogen’s goal to provide affordable and accessible therapies. By leveraging Microsoft’s cutting-edge AI technology, Tevogen aims to push the boundaries of what AI can achieve in the biotech industry.
According to The McKinsey Global Institute, Generative AI could generate $60 billion to $110 billion annually in economic value for the pharmaceutical and medtech companies, with $18 billion to $30 billion of that value attributed to commercial functions alone. Mr. Mehta, a Microsoft alum, added “The metrics are astounding, and we are excited to contribute to that economic value.”
